Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V. Katsaounis P, et al. Among authors: kotsakis a. Cancer Chemother Pharmacol. 2015 Apr;75(4):821-7. doi: 10.1007/s00280-015-2707-x. Epub 2015 Feb 22. Cancer Chemother Pharmacol. 2015. PMID: 25702051 Clinical Trial.
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, Hatzidaki D, Mavroudis D, Georgoulias V; Hellenic Oncology Research Group (HORG). Pallis AG, et al. Among authors: kotsakis a. Lung Cancer. 2008 Dec;62(3):356-63. doi: 10.1016/j.lungcan.2008.03.030. Epub 2008 May 22. Lung Cancer. 2008. PMID: 18501466
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.
Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, Polyzos A, Geroyianni A, Agelidou A, Agelaki S, Kalbakis K, Kotsakis A, Mavroudis D, Georgoulias V. Boukovinas I, et al. Among authors: kotsakis a. Lung Cancer. 2009 Jan;63(1):77-82. doi: 10.1016/j.lungcan.2008.04.006. Epub 2008 May 27. Lung Cancer. 2009. PMID: 18508158 Clinical Trial.
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Xenidis N, Kotsakis A, Kalykaki A, Christophyllakis Ch, Giassas S, Kentepozidis N, Polyzos A, Chelis L, Vardakis N, Vamvakas L, Georgoulias V, Kakolyris S. Xenidis N, et al. Among authors: kotsakis a. Lung Cancer. 2010 Jun;68(3):450-4. doi: 10.1016/j.lungcan.2009.08.012. Epub 2009 Sep 23. Lung Cancer. 2010. PMID: 19783319 Clinical Trial.
Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.
Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, Mavroudis D, Georgoulias V. Pallis AG, et al. Among authors: kotsakis a. Ann Oncol. 2011 Nov;22(11):2448-2455. doi: 10.1093/annonc/mdq772. Epub 2011 Mar 10. Ann Oncol. 2011. PMID: 21393380 Free article.
Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.
Kentepozidis N, Soultati A, Giassas S, Vardakis N, Kalykaki A, Kotsakis A, Papadimitraki E, Pantazopoulos N, Bozionellou V, Georgoulias V. Kentepozidis N, et al. Among authors: kotsakis a. Cancer Chemother Pharmacol. 2012 Jul;70(1):161-8. doi: 10.1007/s00280-012-1896-9. Epub 2012 Jun 3. Cancer Chemother Pharmacol. 2012. PMID: 22660737 Clinical Trial.
Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulias V. Kentepozidis N, et al. Among authors: kotsakis a. Cancer Chemother Pharmacol. 2013 Mar;71(3):605-12. doi: 10.1007/s00280-012-2037-1. Epub 2013 Jan 22. Cancer Chemother Pharmacol. 2013. PMID: 23338050 Clinical Trial.
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
Agelaki S, Kontopodis E, Kotsakis A, Chandrinos V, Bompolaki I, Zafeiriou Z, Papadimitraki E, Stoltidis D, Kalbakis K, Georgoulias V. Agelaki S, et al. Among authors: kotsakis a. Cancer Chemother Pharmacol. 2013 Jul;72(1):45-51. doi: 10.1007/s00280-013-2167-0. Epub 2013 Apr 21. Cancer Chemother Pharmacol. 2013. PMID: 23604531 Clinical Trial.
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katopodis O, Souglakos J, Stathopoulos E, Christopoulou A, Kontopodis E, Kotsakis A, Kalbakis K, Kentepozidis N, Polyzos A, Hatzidaki D, Georgoulias V. Katopodis O, et al. Among authors: kotsakis a. Cancer Chemother Pharmacol. 2014 Aug;74(2):333-40. doi: 10.1007/s00280-014-2509-6. Epub 2014 Jun 15. Cancer Chemother Pharmacol. 2014. PMID: 24930058 Clinical Trial.
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D. Kontopodis E, et al. Among authors: kotsakis a. Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15. Cancer Chemother Pharmacol. 2015. PMID: 25398698 Clinical Trial.
215 results